| Gene symbol | F | Synonyms | None | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_001803.1 (5619..7521) | dbXrefs | |
| Description | Fusion protein (F) | ||||
| GTO ID | GTC3601 |
| Trial ID | NCT06060457 |
| Disease | Respiratory Syncytial Virus Infectious Disease |
| Altered gene | F |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | mRNA-1345 |
| Co-treatment | Fluzone HD |
| Phase | Phase3 |
| Recruitment status | Active, Not Recruiting |
| Title | A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults ≥65 Years of Age |
| Year | 2023 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1345-P304 |
| Vector information | |||
|
|||
| Cohort1: Fluzone HD + mRNA-1345_on Day 1 | |||||||
|
|||||||
| Cohort2: Fluzone HD + placebo_on Day 1 | |||||||
|
|||||||